AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) Sees Significant Decrease in Short Interest

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) saw a large decrease in short interest in the month of June. As of June 15th, there was short interest totaling 3,204,092 shares, a decrease of 54.3% from the May 31st total of 7,013,343 shares. Based on an average daily volume of 51,555,532 shares, the days-to-cover ratio is presently 0.1 days. Currently, 22.0% of the company’s shares are sold short.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Corient Private Wealth LLC purchased a new stake in AIM ImmunoTech during the second quarter valued at about $87,000. DRW Securities LLC increased its stake in AIM ImmunoTech by 60.6% during the fourth quarter. DRW Securities LLC now owns 69,545 shares of the company’s stock worth $79,000 after acquiring an additional 26,254 shares during the last quarter. Finally, Sabby Management LLC purchased a new position in shares of AIM ImmunoTech in the 3rd quarter worth about $79,000. 12.02% of the stock is owned by hedge funds and other institutional investors.

AIM ImmunoTech Stock Performance

Shares of AIM stock opened at $0.31 on Monday. The firm’s 50-day simple moving average is $0.44 and its 200-day simple moving average is $0.82. The company has a debt-to-equity ratio of 0.10, a current ratio of 1.01 and a quick ratio of 1.01. AIM ImmunoTech has a 1-year low of $0.21 and a 1-year high of $20.35. The firm has a market cap of $4.54 million, a P/E ratio of -0.05 and a beta of 1.18.

AIM ImmunoTech (NYSEAMERICAN:AIM) last released its earnings results on Friday, May 15th. The company reported ($0.69) earnings per share (EPS) for the quarter. The company had revenue of $0.02 million for the quarter. As a group, equities analysts forecast that AIM ImmunoTech will post -0.63 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Ascendiant Capital Markets decreased their price objective on AIM ImmunoTech from $10.00 to $9.00 and set a “buy” rating on the stock in a report on Monday, June 1st. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $9.00.

AIM ImmunoTech Company Profile

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.